Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Core Insights - Candel Therapeutics, Inc. reported significant advancements in its clinical pipeline and financial position, with plans for pivotal trials and regulatory submissions in 2026 [2][4]. Financial Performance - Research and development expenses for Q4 2025 were $11.0 million, up from $4.8 million in Q4 2024, and for the full year 2025, they totaled $30.5 million compared to $19.3 million in 2024, primarily due to increased manufacturing and clinical trial costs [8]. - General and administrative expenses rose to $4.7 million in Q4 2025 from $3.3 million in Q4 2024, and for the full year, they were $17.8 million compared to $14.1 million in 2024, driven by higher commercial readiness costs [9]. - The net loss for Q4 2025 was $29.5 million, compared to a net loss of $14.1 million in Q4 2024, while the full year net loss was $38.2 million, down from $55.2 million in 2024, reflecting a shift from net other expense to net other income [10]. Cash Position - As of December 31, 2025, cash and cash equivalents were $119.7 million, an increase from $102.7 million at the end of 2024, with sufficient funds projected to support operations into Q1 2028 [11]. Clinical Development Updates - The company plans to initiate a pivotal phase 3 clinical trial of aglatimagene in NSCLC in Q2 2026 and submit a Biologics License Application (BLA) for aglatimagene in localized prostate cancer in Q4 2026 [4][13]. - Aglatimagene has received Fast Track Designation from the FDA for both prostate cancer and NSCLC, and the company is preparing for a potential commercial launch in 2027 [5][16]. Strategic Funding - Candel secured a $130 million term loan facility with Trinity Capital, with $50 million drawn at closing, and raised approximately $100 million through a follow-on equity offering in February 2026 [4][10]. - A royalty financing agreement with RTW Investments, LP, was established, which will provide additional funding contingent on FDA approval of aglatimagene [4][9]. Upcoming Milestones - The company anticipates presenting follow-up clinical data from its phase 3 trial of aglatimagene in prostate cancer in Q2 2026 and biomarker data in Q3 2026 [5][13].